How Institutions Trade PDUFA Events

Why stocks drop on good news, how short selling works around FDA catalysts, and what retail traders miss.

The Retail Trap

Here's what typically happens to retail biotech traders: They find a stock with an upcoming PDUFA date. They research the drug, read the clinical data, check the AdCom vote. Everything looks bullish. They buy shares. The FDA approves the drug. And the stock drops 20%.

This isn't bad luck. It's a predictable pattern that institutions exploit every PDUFA cycle. Understanding why it happens is the difference between being the person who buys the top and the person who avoids the trap.

How Short Selling Works

Short selling is borrowing shares you don't own, selling them at the current price, and buying them back later at a lower price. The difference is your profit.

When an institution shorts a biotech stock before a PDUFA date, they're betting that even if the drug gets approved, the stock will drop because the approval was already expected. They don't need the drug to fail — they just need the stock to not go up.

Why Stocks Drop on FDA Approval

1. "Buy the rumor, sell the news"

If everyone expects approval, the approval is already reflected in the stock price before the FDA announces it. The announcement itself adds no new information. Smart money sells because the catalyst they were holding for has been consumed.

2. Short sellers pile on after the catalyst

Some institutions specifically wait for approval to initiate short positions. Their thesis: the stock is now at peak optimism, the catalyst is gone, and the hard work of commercialization begins. Most FDA-approved drugs take 12-18 months to generate meaningful revenue. That's a long time for the stock to drift down.

3. Dilution follows approval

Many small-cap biotechs need to raise capital to commercialize their newly approved drug. Within weeks of approval, they announce a secondary offering — issuing new shares that dilute existing holders. Institutions know this is coming. Retail doesn't.

4. The revenue reality check

Approval is just permission to sell the drug. It doesn't guarantee sales. A rare disease drug might treat 5,000 patients globally. An orphan gene therapy might treat 200. The stock was priced as if approval = revenue, but approval just means the work of building a commercial operation begins.

What Short Interest Tells You

Short interest is the percentage of a stock's float that has been sold short. High short interest before a PDUFA can mean two very different things:

The key question isn't "is short interest high?" — it's "is the approval a surprise or not?" High short interest + surprise approval = squeeze. High short interest + expected approval = shorts were right.

How to Use This Information

Before the PDUFA:

Check the Sell-The-News Risk score on every event in the scanner. HIGH risk doesn't mean avoid the trade — it means adjust your expectations. A HIGH STN risk event might still be tradeable if you buy early and sell into the run-up before the decision instead of holding through it.

Position sizing:

LOW STN risk = full conviction size. The approval isn't priced in, the market will be surprised, and the move has room to run.

MODERATE STN risk = standard size. Some upside on approval but don't expect fireworks.

HIGH STN risk = reduce size or skip. If you play it, take profits before the decision or accept that the stock might drop on good news.

The sell-before-the-event strategy:

Many experienced biotech traders buy 2-4 weeks before the PDUFA and sell 1-3 days before the decision. They capture the run-up as retail traders pile in, then exit before the binary event. They don't care if it gets approved or not — they made their money on the momentum leading up to it. This is what institutions do at scale.

The Bottom Line

Institutions have more capital, better data, faster execution, and decades of experience trading FDA events. The playing field isn't level. But it doesn't need to be. You don't need to beat them — you need to stop being their exit liquidity.

Understanding sell-the-news dynamics, short interest mechanics, and dilution risk turns you from a retail trader holding the bag into a retail trader who sees the same playbook institutions are running. The edge isn't inside information — it's pattern recognition applied systematically.

That's what the scanner was built for.